Related Experiment Video
Updated: Sep 23, 2025

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
Orphan GPR146: an alternative therapeutic pathway to achieve cholesterol homeostasis?
Brendan P Wilkins1, Angela M Finch2, Yan Wang3
1Orphan Receptor Pharmacology Laboratory, School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia; Molecular Pharmacology Drug Design, School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia.
Insights
Targeting G protein-coupled receptor 146 (GPR146) may reduce atherosclerosis and lower cholesterol. GPR146 inhibition offers a promising therapeutic strategy for cardiovascular complications, independent of LDL receptors.
Area of Science:
- Cardiovascular Science
- Genetics
- Pharmacology
Background:
- Atherosclerosis leads to heart attack and stroke, with statins offering incomplete treatment, especially for familial hypercholesterolemia (FH).
- Genome-wide association studies identified single nucleotide polymorphisms (SNPs) at G protein-coupled receptor 146 (GPR146) associated with human atherosclerosis.
- The precise role of GPR146 in serum cholesterol homeostasis remained largely unelucidated until recent discoveries.
Purpose of the Study:
- To investigate the role of GPR146 in cholesterol regulation and atherosclerosis.
- To evaluate the therapeutic potential of targeting GPR146 for cardiovascular disease management.
Main Methods:
- Utilized Gpr146 knockout mouse models to assess serum cholesterol levels and atherosclerotic plaque burden.
- Examined the effect of Gpr146 deletion independently of the low-density lipoprotein receptor pathway.
Main Results:
- Gpr146 deletion in mice significantly reduced serum cholesterol levels.
- Atherosclerotic plaque burden was decreased in Gpr146-deficient mice.
- The cholesterol-lowering effect of Gpr146 deletion was independent of the low-density lipoprotein receptor.
Conclusions:
- GPR146 plays a crucial role in regulating serum cholesterol and atherosclerosis.
- Inhibition of GPR146 presents a potential novel therapeutic strategy for managing atherosclerosis and associated cardiovascular risks.
- Further research into GPR146's endogenous ligand may accelerate therapeutic development.
Abstract:
Atherosclerosis predisposes to myriad cardiovascular complications, including myocardial infarction and stroke. Statins have revolutionised cholesterol management but they do not work for all patients, particularly those with familial hypercholesterolaemia (FH). Genome-wide association studies have linked SNPs at orphan G protein-coupled receptor 146 (GPR146) to human atherosclerosis but how GPR146 influences serum cholesterol homeostasis was only recently described. Gpr146 deletion in mice reduces serum cholesterol and atherosclerotic plaque burden, confirming GPR146 as a potential therapeutic target for managing circulating cholesterol. Critically, this effect was independent of the low-density lipoprotein receptor. While still an orphan, the activation of GPR146 by serum suggests identification of its endogenous ligand is tantalisingly close. Herein, we discuss the evidence for GPR146 inhibition as a treatment for atherosclerosis.
Related Concept Videos
Cholesterol: Significance and Regulation
Considering cholesterol and...
GPCR Desensitization
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
GPCRs Regulate Adenylyl Cylase Activity

